Research Topics
Genomes and GenesSpecies | Brigitte Sigal-ZafraniSummaryAffiliation: Institut Curie Country: France Publications
| Collaborators
|
Detail Information
Publications
Histological margin assessment for breast ductal carcinoma in situ: precision and implicationsBrigitte Sigal-Zafrani
Department of Pathology, Institut Curie, 26 Rue d Ulm, 75248 Paris, France
Mod Pathol 17:81-8. 2004..A standard for margin status reporting and pathological processing of screen-detected DCIS in situ lesions will help in the interpretation of data from different institutions...
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literatureYoulia M Kirova
Department of Radiation Oncology, Institut Curie, 26 Rue d Ulm, 75248, Paris Cedex 05, France
Breast Cancer Res Treat 120:119-26. 2010..4 years of follow-up, the rate of ipsilateral tumours was no higher in mutation carriers than in non-carriers or controls. As tumours in BRCA1/2 mutation carriers might be more sensitive to radiation, BCT is a possible treatment option...- Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trialMarc A Bollet
Department of Radiation Oncology, Institut Curie, Paris, France
Radiother Oncol 102:82-8. 2012..This phase II trial aimed to investigate the efficacy of concurrent radio- (RT) and chemotherapy (CT) in the preoperative setting for operable, non-metastatic breast cancer (BC) not amenable to initial breast-conserving surgery (BCS)... - Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery firstMarc A Bollet
Department of Radiation Oncology, Institut Curie, Paris, France
Radiother Oncol 82:272-80. 2007.... - Management of operable invasive breast cancer in women over the age of 70: long-term results of a large-scale single-institution experienceFatima Laki
Department of Surgery, Institut Curie, Paris, France
Ann Surg Oncol 17:1530-8. 2010..This retrospective analysis of a cohort from a single institution was designed to evaluate whether such patients are really undertreated because of their age and to reappraise their usual management... - Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II studyMarc A Bollet
Department of Radiotherapy, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
Eur J Cancer 42:2286-95. 2006..Grade 4 haematological toxicity occurred in 22% of patients. In conclusion, chemoradiotherapy demonstrated good efficacy, both in terms of pCR and in allowing breast conservation with acceptable tolerance... - Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsySeverine Alran
Department of Surgical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
Ann Surg Oncol 14:2195-201. 2007..The purpose of this study was to test the accuracy of the nomogram on patients with macrometastatic and micrometastatic SLN-positive biopsy findings... - Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations statusAlain Fourquet
Departments of Radiation Oncology, Institut Curie, Paris, France
Am J Clin Oncol 32:127-31. 2009..BRCA1/2 germline mutations are associated with impaired DNA double-strand break repair. We tested whether breast cancers in BRCA1/2 mutation carriers were more responsive to induction treatments than in noncarriers... 
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaFabien Reyal
Departement de Chirurgie, Institut Curie, Paris, France
PLoS ONE 7:e35184. 2012..Since most of the genes included in the GG are involved in cell proliferation, we performed a retrospective study to compare the prognostic value of GG, Mitotic Index and Ki67 score...- Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancerChristophe Le Tourneau
Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
Am J Clin Oncol 35:242-6. 2012.... - Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal womenMarc A Bollet
Department of Radiation Oncology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
Radiother Oncol 85:336-45. 2007..This study aimed to evaluate responses and outcome of hormone-therapy (HT) and radiotherapy (RT) given concurrently for large breast cancers in post-menopausal women... - Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatmentMarc A Bollet
Department of Radiation Oncology, Institut Curie, 26 Rue d Ulm, 75248 Paris, France
Breast Cancer Res 11:R54. 2009..We sought to determine whether the levels of expression of 17 candidate genes were associated with locoregional control after breast-conserving treatments of early-stage breast cancers in young, premenopausal women... - The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinomaFabien Reyal
Department of Surgery, Institut Curie, Paris, France
PLoS ONE 6:e20297. 2011..The aim of our work was to decipher the interaction between this classification and the probability of a positive sentinel node biopsy... - Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II studyMarc A Bollet
Department of Radiation Oncology, Institut Curie, Paris, France
Int J Radiat Oncol Biol Phys 69:13-8. 2007.... - A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patientsJean Yves Pierga
Institut Curie, 26 Rue d Ulm, 75005, Paris, France
Breast Cancer Res Treat 122:429-37. 2010..In HER2-positive tumor patients, trastuzumab added to ECD leads to increased pCR rates. It was the only combination to deserve further study according to the two-stage Fleming's design used in this trial... - KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcomeSandy Azoulay
Department of Pathology, Institut Curie, Paris Cedex, France
Mod Pathol 18:1623-31. 2005..This highly specific immunophenotype could be useful to differentiate adenoid cystic carcinoma of the breast from other subtypes of breast carcinoma such as cribriform carcinoma... - Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapseFrançois Clément Bidard
Department of Medical Oncology, Institut Curie, Paris, France
Clin Cancer Res 14:3306-11. 2008..Clinical significance of disseminated tumor cells (DTC) in bone marrow of early breast cancer patients has been reported, but improvements in detection methods are needed... - Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinomaAnne Vincent-Salomon
Department of Pathology, Institut Curie, 75005 Paris Cedex, France
Eur J Cancer 45:1979-86. 2009.... - High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patientsAnne Vincent-Salomon
Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
Breast 21:380-3. 2012..Our aim was to evaluate the risk of relapse for lobular carcinoma in situ (LCIS) patients, diagnosed on mammography performed for microcalcifications and according to proliferation assessed by Ki67 staining... - Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapyAnne Vincent-Salomon
Department of Pathology, Institut Curie, Paris, France
Eur J Cancer 40:1502-8. 2004..The sequential analysis of MI in breast cancers treated by preoperative CT thus provides a surrogate for predicting long-term outcome... - Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsPatricia De Cremoux
Department of Tumour Biology, Institut Curie, Paris 75005, France
BMC Cancer 11:215. 2011..Our aim was to establish the feasibility and reliability of high throughput RNA analysis in a prospective trial... - The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?Carole Massabeau
Department of Radiation Oncology, Institut Curie, 26 Rue d Ulm, Paris, 75005, France
Breast Cancer Res Treat 134:259-66. 2012..0167). Among the low and intermediate grade breast cancers, the FGFR1 negative tumors were resistant to chemoradiotherapy. The expression of FGFR1 in patients' biopsies may serve as a marker of response to chemoradiotherapy... - External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvementDavid Hajage
Department of Biostatistics, Institut Curie, Paris, France
PLoS ONE 6:e27446. 2011..We provide the validation of Adjuvant! Online algorithm on two breast cancer datasets, and we determined whether the accuracy of Adjuvant! Online is improved with other well-known prognostic factors... - Improving the definition of tumor bed boost with the use of surgical clips and image registration in breast cancer patientsYoulia M Kirova
Department of Radiation Oncology, Institut Curie, Paris, France
Int J Radiat Oncol Biol Phys 78:1352-5. 2010..To evaluate the accuracy of a boost technique... - Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosageAmélie Monteau
Department of Radiation Oncology, Institut Curie, Paris, France
Int J Radiat Oncol Biol Phys 75:1021-8. 2009..Following breast-conserving surgery for DCIS, reexcision before radiotherapy is recommended when margins are close or involved. We investigated whether an additional radiation dose could replace reexcision... - Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrumMarick Lae
Service de Pathologie, Section Médicale, Institut Curie, Paris Cedex, France
Mod Pathol 22:291-8. 2009..These results support the hypothesis that secretory breast carcinomas have immunohistochemical and genetic features that distinguish them from other basal-like tumors of the breast... - Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapseFrançois Clément Bidard
Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, 75005, Paris, France
Clin Exp Metastasis 25:871-5. 2008..Dissemination of DTC in other host organ and/or epithelial-mesenchymal transition from cytokeratin-positive to cytokeratin-negative DTC may explain this observation... - Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entityAnne Vincent-Salomon
Department of Tumor Biology, Institut Curie, Paris Cedex 05, France
Breast Cancer Res 9:R24. 2007..The present study was therefore designed to identify phenotypic and genetic alterations that distinguish MBCs from basal-like carcinomas (BLC)... - [Lobular neoplasia]Brigitte Sigal-Zafrani
Institut Curie, 26 Rue d Ulm, 75005 Paris
Ann Pathol 23:547-53. 2003..Mass screening is challenging the current opinion that lobular disease cannot be detected by mammography. This raises the problem of the optimal management of patients with lobular neoplasia on needle core biopsies... - Stereotactic radioguided surgery by siteSelect for subclinical mammographic lesionsVirginie Doridot
Department of General and Breast Surgery, Institut Curie, 26 Rue d Ulm, 75006 Paris, France
Ann Surg Oncol 12:181-8. 2005..We defined the indications for and evaluated the results of a new technique for radioguided surgery, the SiteSelect system. The procedure allows en-bloc resection of the breast parenchyma under local anesthesia... - [Routine sentinel node detection in breast cancer. Experience of the Curie Institute]Sophie Delahaye
, Institut Curie, 26, rue d'Ulm, 75005 Paris, France
Bull Cancer 91:641-7. 2004..This article is an evaluation of the sentinel lymph node technique in a specialized Center providing a breakdown of the strong points and weak points of the procedure... - MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapyFabienne Thibault
Department of Medical Imaging, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
AJR Am J Roentgenol 183:1159-68. 2004..Our objective was to study the impact on surgical planning of adding serial MRI evaluations of the tumor to standard non-MRI assessments... - High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancersMarc A Bollet
Département d Oncologie Radiothérapie, Institut Curie, 26, rue d Ulm, 75248 Paris Cedex 05, France
J Natl Cancer Inst 100:48-58. 2008..To distinguish new primary breast cancers from true recurrences, pangenomic analyses of DNA copy number alterations (CNAs) using single-nucleotide polymorphism arrays have proven useful... - Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevanceValerie Choesmel
UMR144 CNRS, Research Division, Institut Curie, Paris, France
Breast Cancer Res 6:R556-70. 2004..In the present study, we have assessed the clinical relevance of current methods aimed at detecting rare disseminated carcinoma cells... - Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapyYoulia M Kirova
Department of Radiation Oncology, Institut Curie, 26 Rue d Ulm, 75248 Paris, Cedex 05, France
Eur J Cancer 41:2304-11. 2005..Therefore, breast-conserving treatment can be offered to these patients. However, longer follow-up is needed to ensure that the rate of new primary cancer in the treated breast does not increase in the long-term... - No evidence of human papillomavirus DNA sequences in invasive breast carcinomaPatricia De Cremoux
Department of Tumour Biology, Institut Curie, 26, rue d Ulm, 75248, Paris Cedex 05, France
Breast Cancer Res Treat 109:55-8. 2008..No HPV-DNA sequences were detected in our series of 50 samples. These data argue against the role of oncogenic HPV in the pathogenesis of breast cancer... - Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcomePascale This
Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248, Paris Cedex 05, France
Fam Cancer 11:473-82. 2012..However, good compliance with prophylactic salpingo-oophorectomy was observed. This study confirms the high breast cancer risk in these women... - Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breastAnne Vincent-Salomon
Institut Curie, Department of Tumor Biology, Paris, France
Clin Cancer Res 14:1956-65. 2008..To gain insight into genomic and transcriptomic subtypes of ductal carcinomas in situ of the breast (DCIS)... - Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classificationFabien Reyal
Department of Surgery, Institut Curie, Paris, France
PLoS ONE 7:e47390. 2012.... - Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationTatiana Popova
Authors Affiliations Centre de Recherche, INSERM U830, Departments of Tumor Biology, Translational Department, and Radiotherapy, Institut Curie, Sorbonne Paris Cité, University Paris Descartes, Paris and Institut Bergonié, Bordeaux, France
Cancer Res 72:5454-62. 2012..This assay may ease the challenge of selecting patients for genetic testing or recruitment to clinical trials of novel emerging therapies that target DNA repair deficiencies in cancer. Cancer Res; 72(21); 5454-62. ©2012 AACR... - Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervixChristophe Rosty
, Institut Curie, , Paris, France
Int J Gynecol Pathol 23:13-7. 2004..Overexpression/amplification of HER-2/neu is uncommon in invasive cervical carcinoma, suggesting that there is little indication for using anti-p185c-erbB2 therapy in the treatment of these patients... - Breast lesions: quantitative elastography with supersonic shear imaging--preliminary resultsAlexandra Athanasiou
Department of Radiology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
Radiology 256:297-303. 2010.... - [Shared responsibility for follow-up of breast cancer patients. Experience of the Institut Curie]Cyrus Chargari
Departement de Radiotherapie, Institut Curie, Paris, France
Bull Cancer 95:1047-51. 2008..We herein present the preliminary results of this strategy, and demonstrate that partially transferring primary responsibility for follow-up does not compromise its quality... - Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practicePaul Freneaux
Department of Pathology, Institut Curie, Paris, France
Mod Pathol 15:641-6. 2002..The clinical significance of occult metastases in SN needs to be specified by long-term follow-up analysis... - Search for a gene expression signature of breast cancer local recurrence in young womenNicolas Servant
Institut Curie, CNRS, Paris, France
Clin Cancer Res 18:1704-15. 2012..We evaluated this signature on both another platform and an independent series, compared its performance with other published gene-sets, and investigated the gene expression profile of a larger data set... - HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processAnne Vincent-Salomon
Department of Pathology, Institut Curie, Paris, France
Cancer 94:2169-73. 2002..In a few patients, a diminution in the level of HER2 expression was observed after CT or in secondary tumors. This may have been due to a transitory state of altered tumor cells or to the selection of HER2 negative tumor cells clones... - Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumorsNathalie T Joncker
Laboratoire d'Immunologie, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
Int J Cancer 118:1205-14. 2006..These results suggest that to find activated effector T cells in a tissue does not always mean that a specific immune response is taking place... - Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patientsPatricia De Cremoux
Departement de Biologie des Tumeurs, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex, France
Anticancer Res 29:1475-82. 2009..This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients... - [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]Patricia De Cremoux
, Institut Curie, 26, rue d'Ulm, 75005 Paris, France
Bull Cancer 91:917-27. 2004..These trials were either comparative (for anastrozole) or sequential (for anastrozole, letrozole and exemestane). The issues of long term adverse effects (bone) and hormone treatment sequence remain to be addressed... - Ductal breast carcinoma develops through different patterns of chromosomal evolutionRomain Molist
FRE 2584 CNRS, Institut Curie, Paris, France
Genes Chromosomes Cancer 43:147-54. 2005..Chromosomes 5, 7, 8, and 20 were the most frequently gained. Our findings support the evidence of a new pathway of chromosomal evolution in a small subset of ductal breast carcinomas characterized by numerical chromosome aberrations... - Late malignant melanoma after treatment of rhabdomyosarcoma of the orbit during childhoodLivia Lumbroso
Institut Curie, 26 rue d'Ulm, 75005 Paris, France
Arch Ophthalmol 120:1087-90. 2002